慢性气道黏液高分泌分子机制及治疗进展  

Advances in molecular mechanism and treatment of chronic mucus hypersecretion

作　　者：岳雪亭 邹祥阳 朱广林 陈东海 董宇超 韩一平 张景熙 Yue Xueting;Zou Xiangyang;Zhu Guanglin;Chen Donghai;Dong Yuchao;Han Yiping;Zhang Jingxi(Department of Respiratory and Critical Care Medicine the First Affiliated Hospital of Navy Military Medical University,Shanghai 200433,China;Nanjing′s Second Retired Cadres′Center of Jiangsu Province Military Command,Nanjing 210009,China)

机构地区：[1]海军军医大学第一附属医院呼吸与危重症医学科,上海200433 [2]江苏省军区南京第二离职干部休养所,南京210009

出　　处：《中华结核和呼吸杂志》2023年第12期1272-1278,共7页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：上海市科技计划项目 (22ZR1478300)。

摘　　要：慢性阻塞性肺疾病(简称慢阻肺)是我国发病率和病死率居高不下的慢性病之一,给社会带来了沉重的经济负担。研究发现慢性气道黏液高分泌(CMH)是造成慢阻肺患者临床症状持续存在、生活质量较差、肺功能快速下降、急性加重和住院频率增加的独立危险因素。CMH是慢阻肺具有特殊病理生理改变的临床表型。目前关于CMH的形成机制尚不明确,治疗上缺乏特异、有效的针对性措施。本文拟从CMH概述、对慢阻肺患者造成的影响、形成的分子机制及治疗现状与进展等角度对近期国内外关于CMH的最新研究结论进行综述,并探讨CMH治疗的潜在靶点,为改善CMH及治疗慢阻肺提供新思路与方向。Chronic obstructive pulmonary disease(COPD)is one of the chronic diseases with high morbidity and mortality in China,which imposes heavy economic burden on society.Research has shown that chronic mucus hypersecretion(CMH)is an independent risk factor for persistent clinical symptoms,poor quality of life,rapid decline in lung function,acute exacerbation and increased hospitalization rate in COPD patients.CMH is a clinical phenotype of COPD with specific pathological and physiological changes.At present,the formation mechanism of CMH is not clear.There is a lack of specific and effective targeted treatments.This article aimed to review the latest research findings on CMH at home and abroad from the overview,impact on COPD patients,molecular mechanisms of formation,current treatment status and progress,and discuss potential targets for CMH treatment,to provide new ideas and directions for improving CMH and treating COPD.

关 键 词：气道黏液高分泌 慢阻肺患者 临床表型 慢性阻塞性肺疾病 分子机制 临床症状 治疗进展 慢性病 

分 类 号：R56[医药卫生—呼吸系统]